Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia

Abstract

CD55 and CD59 are glycophosphatidylinositol-anchored proteins with complement inhibitory properties. Lymphopenia in systemic lupus erythematosus (SLE) has been associated with autoantibodies targeting nuclear antigens. The aim of this study was to evaluate the surface density of CD55 and CD59 in T and B lymphocytes from patients with SLE and lymphopenia and its possible correlation with the presence of common SLE autoantibodies. Flow cytometric analyses were performed on CD55 and CD59 stained CD3 and CD19 cells from 40 SLE patients, 30 with lymphopenia and 10 without it, and 25 healthy controls. Autoantibodies were detected in the sera by enzyme linked immunosorbent assay. The mean fluorescence intensity of CD55 and CD59 in T and B cells was significantly diminished in SLE patients with lymphopenia when compared with healthy subjects. Interestingly, the opposite was found in T and B cells from non-lymphopenic SLE patients. Although there was no correlation between CD55 and CD59 surface density and the presence of any specificity of the autoantibodies tested, higher titres of anti-dsDNA, anti-SM and anti-ribosomal p antibodies were significantly associated with lymphopenia. The deficiency of CD55 and CD59 expression may play a role in the pathophysiology of lymphopenia, most likely by increasing the susceptibility of cells to complement mediated cytolysis.

Keywords

systemic lupus erythematosus CD55 CD59 lymphopenia autoantibodies

Get full access to this article

View all access options for this article.

References

Osman C , Swaak AJG. Lymphocytotoxic antibodies in SLE: a review of the literature . Clin Rheumatol 1994; 13: 21-27 .

Rivero SJ , Diaz-Jouanen E , Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus . Arthritis Rheum 1978; 21: 295-305 .

Drenkard C , Villa AR , Garcia-Padilla C , Perez-Vazquez ME , Alarcon-Segovia D. Remission of systemic lupus erythematosus . Medicine (Baltimore) 1996; 75: 88-98 .

Winfield JB. Antilymphocyte autoantibodies. In Wallace DJ, Hahn BH eds. Dubois’ lupus erythematosus. Williams and Wilkins, 1997: 505-515.

Liszewski MK , Farries TC , Lublin DM , Rooney IA , Atkinson JP. Control of the complement system . Adv Immunol 1996; 61: 201-283 .

Song WC. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury . Curr Dir Autoimmun 2004; 7: 181-199 .

Nicholson-Weller A , Wang CE. Structure and function of decay accelerating factor CD55 . J Lab Clin Med 1994; 123: 485-491 .

Davies A , Lachmann PJ. Membrane defense against complement lysis: The structure and biological properties of CD59 . Immunol Res 1993; 12: 258-275 .

Karadimitris A , Luzzatto L. The cellular pathogenesis of paroxysmal nocturnal hemoglobinuria . Leukemia 2001; 15: 1148-1152 .

10.

Richaud-Patin Y , Perez-Romano B , Carrillo-Maravilla E et al. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus . Immunol Lett 2003; 88: 95-99 .

11.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of SLE . Arthritis Rheum 1982; 25: 1271-1277 .

12.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee of Prognosis Studies in SLE . Arthritis Rheum 1992; 35: 630-640 .

13.

Kim DD , Song WC. Membrane complement regulatory proteins . Clin Immunol 2006; 118: 127-136 .

14.

Nagakura S , Nakakuma H , Horikawa K. Expression of decay-accelerating factor and CD59 in lymphocytes subsets in healthy individual and paroxysmal nocturnal hemoglubinuria patients . Am J Hematol 1993; 43: 14-18 .

15.

Clarkson NA , Kaufman R , Lublin DM et al. Characterization of the echovirus 7 receptor: domains of CD55 is critical for virus binding . J Virol 1995; 69: 5497-5501 .

16.

Shafren DR , Bates RC , Agrez MV , Herd RL , Burns GF , Barry RD. Coxsackie viruses B1, B3 and B5 use decay accelerating factor as a receptor for cell attachment . J Virol 1995; 69: 3873-3877 .

17.

Arora M , Arora R , Tiwari SC , Das N , Srivastava LM. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis . Lupus 2000; 9: 127-131 .

18.

Cuida M , Legler DW , Eidsheim M , Jonsson R. Complement regulatory proteins in the salivary glands and saliva of Sjögren’s syndrome patients and healthy subjects . Clin Exp Rheumatol 1997; 15: 615-623 .

19.

Li SH , Szmitko PE , Weisel RD et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells . Circulation 2004; 109: 833-836 .

20.

van Beek J , van Meurs M , ‘t Hart VA et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation . J Immunol 2005; 174: 2353-2365 .

21.

Tsunoda S , Kawano M , Koni I et al. Diminished expression of CD59 on activated CD8 T-cells undergoing apoptosis in systemic lupus erythematosus and Sjögren’s syndrome . Scand J Immunol 2000; 51: 293-299 .

22.

Wenzel J , Gerdsen R , Uerlich M , Bauer R , Tueting T , Bieber T. Lymphocytopenia in lupus erythematosus: close in vivo association to autoanti-bodies targeting nuclear antigens . Br J Dermatol 2004; 150: 994-998 .

23.

Böhm I. Apoptosis: The link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus . Scand J Rheumatol 2004; 33: 409-416 .

24.

Alarcon-Segovia D , Llorente L , Ruiz-Argüelles A. The penetration of autoantibodies may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage . J Autoimmun 1996; 9: 295-300 .